Grifols S.A. is a global healthcare company that specializes in the development, production, and marketing of plasma-derived therapies and other innovative healthcare solutions. The company focuses on treating a variety of health conditions, including immune deficiencies, hemophilia, and other chronic diseases, by harnessing the therapeutic potential of human plasma. Grifols is also involved in the manufacture of diagnostic tools and systems, contributing to improved patient care and disease management. With a commitment to research and development, Grifols aims to advance the field of medicine through cutting-edge technologies and a robust portfolio of life-saving products.
Brookfield Asset Management is reportedly pursuing €9.5 billion in debt financing for a potential take-private deal for Grifols. The deal could lead to major financial restructuring, impacting bondholders and shareholders amid scrutiny of Grifols' high debt levels and credit downgrades.
Grifols reveals Brookfield Capital's preliminary discussions with major shareholders about a potential joint bid to delist the company from Spanish stock exchanges and NASDAQ. An exclusivity agreement has been signed, and due diligence is underway, with the deal estimated at 5.5 billion euros.
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.
